Fund shareholders of GT BIOPHARMA INC
ISIN US36254L3087 · United States · LEI 549300HMPDDS7IM47Y18
- Fund shareholders
- 4
- Of which ETFs
- 0 4 other funds
- Value held
- 197.6K $
- Share of capital
- 1.1 % of 45.1M shares on Aug 10, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 451,875 | 184.4K $ | 0.00 % | 1.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 21,852 | 10.4K $ | 0.05 % | as of Feb 28, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 3,559 | 1.7K $ | 0.01 % | as of Feb 28, 2026 ↗ | |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 2,196 | 1K $ | 0.00 % | as of Feb 28, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 4 | 0 | 479,482 | +1,766.5 % |
| 2026Q1 | 4 | 0 | 25,689 | 0.0 % |
| 2025Q4 | 4 | -1 | 25,689 | -18.2 % |
| 2025Q3 | 5 | 0 | 31,412 | +13.2 % |
| 2025Q2 | 5 | +1 | 27,750 | +11.1 % |
| 2025Q1 | 4 | -1 | 24,980 | +6.1 % |
| 2024Q4 | 5 | 0 | 23,548 | +11.1 % |
| 2024Q3 | 5 | -2 | 21,197 | -32.2 % |
| 2024Q2 | 7 | 31,273 |
Institutional managers
36 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 294,459 | 120.2K $ | as of Mar 31, 2026 |
| Arax Advisory Partners | 93,627 | 38.2K $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 66,165 | 27K $ | as of Mar 31, 2026 |
| SeaCrest Wealth Management, LLC | 50,000 | 20.4K $ | as of Mar 31, 2026 |
| UBS Group AG | 45,970 | 18.8K $ | as of Mar 31, 2026 |
| TWO SIGMA SECURITIES, LLC | 31,796 | 13K $ | as of Mar 31, 2026 |
| LPL Financial LLC | 30,382 | 12.4K $ | as of Mar 31, 2026 |
| Invst, LLC | 23,400 | 9.6K $ | as of Mar 31, 2026 |
| OSAIC HOLDINGS, INC. | 21,000 | 8.6K $ | as of Mar 31, 2026 |
| Cerity Partners LLC | 20,023 | 8.2K $ | as of Mar 31, 2026 |
| Integrated Wealth Concepts LLC | 20,006 | 8.2K $ | as of Mar 31, 2026 |
| Private Wealth Management Group, LLC | 20,000 | 8.2K $ | as of Mar 31, 2026 |
| Coston, McIsaac & Partners | 17,092 | 6 $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 16,599 | 6.8K $ | as of Mar 31, 2026 |
| Caitlin John, LLC | 16,500 | 6.7K $ | as of Mar 31, 2026 |
| WELLS FARGO & COMPANY/MN | 16,037 | 6.5K $ | as of Mar 31, 2026 |
| AM INVESTMENT STRATEGIES LLC | 15,000 | 6 $ | as of Mar 31, 2026 |
| Virtu Financial LLC | 14,876 | 6 $ | as of Mar 31, 2026 |
| StoneX Group Inc. | 14,756 | 6K $ | as of Mar 31, 2026 |
| Verdence Capital Advisors LLC | 12,000 | 4.9K $ | as of Mar 31, 2026 |
| Prospera Financial Services Inc | 11,996 | 4.9K $ | as of Mar 31, 2026 |
| LaSalle St. Investment Advisors, LLC | 11,000 | 4.5K $ | as of Mar 31, 2026 |
| PARSONS CAPITAL MANAGEMENT INC/RI | 10,900 | 4.4K $ | as of Mar 31, 2026 |
| HBK Sorce Advisory LLC | 10,000 | 3.8K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 8,408 | 3.4K $ | as of Mar 31, 2026 |
Cite this page
Titelia. "Fund shareholders of GT BIOPHARMA INC". https://titelia.com/en/stocks/gt-biopharma-inc-US36254L3087